foxo4 dri senolytic peptide human trial 2024 2025

foxo4 dri senolytic peptide human trial 2024 2025 FOXO4-DRI UK | Research Molecular modelling of the FOXO4-TP53

Name: foxo4 dri senolytic peptide human trial 2024 2025 FOXO4-DRI UK | Research Molecular modelling of the FOXO4-TP53
Brand: equiscorp.hu
SKU: 33820717765
Price: 25.80 USD
Availability: InStock
Rating: 4.621 (19 reviews)

Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC

SKU: 33820717765 · From equiscorp.hu

4.6

USD25.80 USD53.80

Pay in 4 interest-free payments of $6.45 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

GMP certified / 99% HPLC purity / Pan-India delivery / Cash on Delivery available Research Use Only This product is intended solely for laboratory and research purposes

Animal Research Context Published preclinical studies typically use 2.5 to 10mcg per kilogram of body weight

Studies indicate that GHK-Cu may stimulate the production of collagen types I, III, and V, as well as elastin, decorin, and glycosaminoglycans in fibroblast cell cultures